Poly Medicure Limited has informed the Exchange regarding a press release dated May 06, 2025, titled "Press Release for the Audited Financial Results (Standalone & Consolidated) for Fourth Quarter and Financial Year ended on March 31, 2025".
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure reported strong FY2025 results, with consolidated revenue growing 21% YoY to Rs. 1,669.8 crores and Q4 revenue up 17% to Rs. 440.8 crores. EBITDA grew 27% for the full year to Rs. 452.8 crores with margins expanding by 113 basis points to 27.1%. Profit after tax surged 31% YoY in FY25 to Rs. 338.6 crores, with Q4 PAT up 34% to Rs. 91.8 crores and PAT margin improving by 270 basis points to 20.8%. The renal division posted standout growth of 60-69%, while the company commercialized two new divisions in cardiology and critical care. The balance sheet remains robust with Rs. 1,220 crores in liquidity and Rs. 325 crores invested in capex for three new plants.
This is a strong, broad-based earnings beat with double-digit revenue growth, expanding margins, and improving return ratios (RoCE of 23.4%), which should be viewed positively by shareholders. However, management flagged short-term demand uncertainty in export markets due to US tariffs and geopolitical tensions, which could weigh on near-term sentiment.